Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones
CME in Minutes: Education in Oncology & Hematology

CME in Minutes: Education in Oncology & Hematology

Answers in CME

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
bookmark
Share icon

All episodes

Best episodes

Top 10 CME in Minutes: Education in Oncology & Hematology Episodes

Goodpods has curated a list of the 10 best CME in Minutes: Education in Oncology & Hematology episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to CME in Minutes: Education in Oncology & Hematology for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite CME in Minutes: Education in Oncology & Hematology episode by adding your comments to the episode page.

Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.
bookmark
plus icon
share episode
Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients.
bookmark
plus icon
share episode
Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care
bookmark
plus icon
share episode
Please visit answersincme.com/860/93496951-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC; and Describe practical, data-driven approaches to effectively integrate current and emerging ADCs into the management of advanced NSCLC.
bookmark
plus icon
share episode
Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the significance of the latest clinical data of perioperative immunotherapeutic approaches in patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.
bookmark
plus icon
share episode
Please visit answersincme.com/TBY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in colorectal cancer discuss management of patients with metastatic disease in the third line and beyond. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with metastatic colorectal cancer (mCRC); Review the clinical implications of the latest evidence for later-line treatments for patients with mCRC; and Outline evidence-based approaches to improve long-term response rates in later-line treatment of mCRC.
bookmark
plus icon
share episode
CME in Minutes: Education in Oncology & Hematology - Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma
play

10/28/24 • 13 min

Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.
bookmark
plus icon
share episode
Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.
bookmark
plus icon
share episode
Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.
bookmark
plus icon
share episode
Please visit answersincme.com/BHU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lymphoma discusses the treatment landscape for CD30-positive peripheral T-cell lymphoma (PTCL). Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations for frontline treatment of PTCL; Describe the clinical evidence informing the use of CD30-directed therapy in frontline treatment of PTCL; and Outline considerations to optimize outcomes with CD30-directed therapy for frontline treatment of patients with PTCL.
bookmark
plus icon
share episode

Show more best episodes

Toggle view more icon

FAQ

How many episodes does CME in Minutes: Education in Oncology & Hematology have?

CME in Minutes: Education in Oncology & Hematology currently has 115 episodes available.

What topics does CME in Minutes: Education in Oncology & Hematology cover?

The podcast is about Life Sciences, Health & Fitness, Cme, Cancer, Medicine, Podcasts, Science, Oncology and Medical Education.

What is the most popular episode on CME in Minutes: Education in Oncology & Hematology?

The episode title 'Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective' is the most popular.

What is the average episode length on CME in Minutes: Education in Oncology & Hematology?

The average episode length on CME in Minutes: Education in Oncology & Hematology is 15 minutes.

How often are episodes of CME in Minutes: Education in Oncology & Hematology released?

Episodes of CME in Minutes: Education in Oncology & Hematology are typically released every 4 days.

When was the first episode of CME in Minutes: Education in Oncology & Hematology?

The first episode of CME in Minutes: Education in Oncology & Hematology was released on Aug 2, 2022.

Show more FAQ

Toggle view more icon

Comments